The lack of statistically significant effect on this outcome, which was repeatedly demonstrated to improve in the CVOTs with GLP-1 RAs [12], can be explained by the irregularity of UACR sampling in real-world setting compared with CVOTs
(Left) In liver cells, GLP-1 can mediate cholesterol efflux by acting directly on LXR, or by inducing an increase in ATP-binding cassette transporter A1 (ABCA1) mRNA through Ca2+/calmodulin (CaM)-dependent protein kinase kinase/CAM-dependent protein kinase IV/Prolactin regulatory element binding (CaMKK/CaMKIV/PREB), increasing apolipoprotein AI (apo AI) mRNA and promoter expression, and increasing apo AI secretion, thereby mediating intracellular cholesterol efflux
For example, if a medication has a half-life of 6 days , that means 50% of the drug is gone 6 days after the injection , 75% is gone by day 12, and so on
Far from being a short term solution, injectables are now at the centre of modern drug delivery particularly for biologics and advanced therapies
There is also an eGuide to Dealing with Depression
What should I do if I'm interested in GLP-1 therapy
